Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05902221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Study acronym: RIFACute
StatusRecruiting
PhasePhase 3
Started2024-05-02
View on ClinicalTrials.gov ↗

Amendment history

2026-06-18
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-07-01→2028-05
Completion date2027-07-01→2028-05
Start dateestimated 2024-03-30→confirmed 2024-05-02
Study sites12→13
2024-03-12
minor
Study Status v1
Start date2023-07-01→2024-03-30
2023-06-05
minor
Original filing
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.
Trial Details
NCT Number NCT05902221
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Infections Joint Prosthetic
Enrollment 235 participants
Start Date 2024-05-02
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-22